PubMed Health⌕ Search

Biomedical subjects

Frantisek Jelínek

Publications and source records attributed to Frantisek Jelínek.

2 recordsLinked to original sources

Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras.

A better understanding of the molecular basis of tumor progression and invasion is needed to improve therapy for malignant tumors. Recently, we established a mouse metastatic MK16 model by transduction of secondary kidney cells with human papillomavirus type 16 (HPV16) E6 and E7 oncogenes and human H-ras activated by G12V mutation. In this study, we extended the model to MK16 cell lines derived from lung metastases and compared the oncogenicity of seven cell lines successively isolated from primary tumors or metastases. By observing the formation and growth of subcutaneous tumors and generation of lung metastasis, we showed a gradual increase in oncogenicity of MK16 cell lines. Interestingly, we demonstrated metastatic potential of MK16/A cells with low oncogenic potential in primary tumor development. To detect changes in gene expression associated with increasing oncogenicity of MK16 cell lines, we performed transcriptional profiling with the Atlas Plastic Mouse 5K microarray. We found that a substantial proportion of up-regulated genes encoded ribosomal proteins. Among the down-regulated genes, the highest number (n=10) belonged to a group coding for transcription factors. Expression of two of these, Pou3f2 and Gtl3, was reduced both in cells derived from primary tumors and those isolated from metastases. Furthermore, microarray hybridization suggested that the down-regulation of cyclin-dependent kinase inhibitors p16(Ink4a) and p57(Kip2) and up-regulation of A6 and A10 members of the S100 protein family might play a role in the increase of MK16 oncogenicity.

Animals↗

Postinflammatory sarcoma in cats.

Histological examination of 38 nodular formations extirpated from the site of vaccine administration to cats disclosed 25 cases of sarcoma and 13 of granuloma. Average age of the cats bearing sarcoma was 8.75 years whereas granuloma occurred at average age of 1.9 year. This age-relationship of the lesions, as well as their similar morphologic features indicated a progression of chronic inflammatory changes to tumors. Similar tumors were diagnosed in one cat with "posttraumatic ocular sarcoma" and in the uterus of female-cat with long-standing pyometra. These two cats were 15 and 8 years old, respectively. Experimental study of local reaction 21 days after administration of commercial, lipid-adjuvanted vaccine revealed in young cats (age 9 months) a reaction to immunogen, whereas in old animals (age 10 to 15 years) there was a reaction to foreign material. The data suggest that chronic inflammation and age-related immunodeficiency are instrumental in pathogenesis of the vaccine-associated sarcoma.

Acid Phosphatase↗